drugset / Trial / NCT03889470

Nitroglycerin as Spasmolytic Regimen for RAS Prevention in Radial Center

NCT03889470 ↗

Phase 4 Unknown 1000 enrolled Hermina Heart Center Kemayoran
RandomizedParallel-groupSingle-blindPrevention

Summary

The investigators will investigate whether administration of Nitroglycerin (NTG) as spasmolytic regimen reduces the incidence of moderate to severe radial artery spasm (RAS) in patients undergoing transradial catheterization in radial center.

Timeline

Start
2018-03-31
Primary completion
2019-09-30
Completion
2019-10-01

Drugs

EvaluationDrugModalityDoseRoute
Comparator NTG Unknown 200 ug Other

Indications

No indication recorded.